VIIBRYD Dosage & Rx Info | Uses, Side Effects

Viibryd Generic Name & Formulations

Legal Class

General Description

Vilazodone HCl 10mg, 20mg, 40mg; tabs.

Pharmacological Class

Selective serotonin reuptake inhibitor + 5-HT_1A receptor partial agonist.

How Supplied

Tabs—30; Patient Starter Kit (7×10mg tabs + 7×20mg tabs + 16×40mg tabs; 7×10mg tabs + 23×20mg tabs)—30

Manufacturer

AbbVie

Generic Availability

YES

Mechanism of Action

The mechanism of action of vilazodone in the treatment of major depressive disorder is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake.

Viibryd Indications

Indications

Major depressive disorder (MDD).

Viibryd Dosage and Administration

Adult

Take with food. Initially 10mg once daily for 7 days, then 20mg once daily for 7 days, then increase to 40mg once daily. Concomitant strong CYP3A4 inhibitors: max 20mg once daily. Concomitant strong CYP3A4 inducers for >14 days: consider increasing dose up to 2-fold over 1–2 weeks; max 80mg daily. Readjust to original level when CYP3A4 inhibitors or inducers (in 14 days) are discontinued.

Children

Not established.

Viibryd Contraindications

Contraindications

During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of vilazodone. Concomitant linezolid or IV methylene blue.

Viibryd Boxed Warnings

Boxed Warning

Suicidal thoughts and behaviors.

Viibryd Warnings/Precautions

Warnings/Precautions

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. History of mania/hypomania. Seizure disorder. Risk for bleeding events. Angle-closure glaucoma. Volume depleted. Sexual dysfunction. Avoid abrupt disruption. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Pregnancy: effects on neonates exposed in 3^rdtrimester (see full labeling). Nursing mothers.

Viibryd Pharmacokinetics

Absorption

Median peak concentrations occurred at 4–5 hours after administration. Absolute bioavailability: 72% with food.

Distribution

Widely distributed. Plasma protein bound: ~96–99%.

Metabolism

Hepatic (CYP3A4).

Elimination

Renal. Fecal. Half-life: ~25 hours.

Viibryd Interactions

Interactions

See Contraindications. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin (monitor), other anticoagulants. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole); see Adult. Antagonized by strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin); see Adult. Monitor digoxin. Caution with other highly protein-bound drugs.

Viibryd Adverse Reactions

Adverse Reactions

Diarrhea, nausea, vomiting, insomnia, headache; hyponatremia/SIADH (esp. in elderly).

Viibryd Clinical Trials

See Literature

Viibryd Note

Not Applicable

Viibryd Patient Counseling